Clinical Trial: DALY II Japan/MB-CART2019.1 for DLBCL

U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288879) titled 'DALY II Japan/MB-CART2019.1 for DLBCL' on Nov. 20.

Brief Summary: DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.

Study Start Date: Dec. 10

Study Type: INTERVENTIONAL

Condition: DLBCL - Diffuse Large B Cell Lymphoma CAR T Cell Therapy

Intervention: BIOLOGICAL: MB-CART2019.1

CAR T cell therapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Miltenyi Biomedicine GmbH

Disclaimer: Curated b...